静脉替罗非班与安慰剂在血管内取栓前对大血管闭塞性卒中功能结局的影响:RESCUE BT随机临床试验
RESCUE BT为研究者发起、随机、双盲、安慰剂对照试验,在中国55家医院纳入948例发病24小时内 proximal intracranial 大血管闭塞卒中患者,随机接受静脉替罗非班(n=463)或安慰剂(n=485)后行血管内取栓。主要终点90天改良Rankin量表评分分布中,替罗非班组与安慰剂组中位数均为3(IQR 1-4),校正共同比值比1.08(95%CI 0.86-1.36),无显著差异。主要安全终点48小时内症状性颅内出血替罗非班组9.7% vs 安慰剂组6.4%(差值3.3%,95%CI -0.2%至6.8%)。结论认为取栓前静脉替罗非班未显著改善90天残疾严重程度,不支持该用法。
要点
- 948例发病24小时内大血管闭塞卒中患者取栓前随机接受静脉替罗非班(n=463)或安慰剂(n=485)。
- 90天改良Rankin量表评分中位数替罗非班组3(IQR 1-4)vs 安慰剂组3(IQR 1-4),校正共同OR 1.08(95%CI 0.86-1.36),无显著差异。
- 48小时内症状性颅内出血替罗非班组9.7% vs 安慰剂组6.4%,差值3.3%(95%CI -0.2%至6.8%)。
- 结论:取栓前静脉替罗非班未显著改善90天残疾严重程度,不支持取栓前静脉使用替罗非班。
适用人群与场景
- 发病24小时内、经最后已知正常时间确认的急性缺血性卒中、 proximal intracranial 大血管闭塞、拟行血管内取栓的患者,来自中国55家医院,共948例(平均年龄67岁,女性391例[41.2%])。
处置流程与药物剂量
- 血管内取栓前给予静脉替罗非班(n=463)或安慰剂(n=485);原文未写明替罗非班的剂量、给药途径细节、输注时长或目标值。
研究设计与关键结果
- 研究者发起、随机、双盲、安慰剂对照试验,中国55家医院,纳入948例发病24小时内 proximal intracranial 大血管闭塞卒中患者,2018年10月10日至2021年10月31日招募,末次随访2022年1月15日。
- 主要终点90天改良Rankin量表评分分布:替罗非班组中位数3(IQR 1-4)vs 安慰剂组3(IQR 1-4);校正共同比值比1.08(95%CI 0.86-1.36)。
- 主要安全终点48小时内症状性颅内出血:替罗非班组9.7% vs 安慰剂组6.4%,差值3.3%(95%CI -0.2%至6.8%)。
- 948例(100%)完成试验。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照试验(RESCUE BT);原文未报告证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,对于拟行血管内取栓的大血管闭塞急性缺血性卒中患者,取栓前静脉替罗非班与安慰剂相比90天残疾严重程度无显著差异,该发现不支持取栓前静脉使用替罗非班。
指南或共识出处
- RESCUE BT随机临床试验,中国临床试验注册号ChiCTR-IOR-17014167。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Tirofiban is a highly selective nonpeptide antagonist of glycoprotein IIb/IIIa receptor, which reversibly inhibits platelet aggregation. It remains uncertain whether intravenous tirofiban is effective to improve functional outcomes for patients with large vessel occlusion ischemic stroke undergoing endovascular thrombectomy.
OBJECTIVE: To assess the efficacy and adverse events of intravenous tirofiban before endovascular thrombectomy for acute ischemic stroke secondary to large vessel occlusion.
DESIGN, SETTING, AND PARTICIPANTS: This investigator-initiated, randomized, double-blind, placebo-controlled trial was implemented at 55 hospitals in China, enrolling 948 patients with stroke and proximal intracranial large vessel occlusion presenting within 24 hours of time last known well. Recruitment took place between October 10, 2018, and October 31, 2021, with final follow-up on January 15, 2022.
INTERVENTIONS: Participants received intravenous tirofiban (n = 463) or placebo (n = 485) prior to endovascular thrombectomy.
MAIN OUTCOMES AND MEASURES: The primary outcome was disability level at 90 days as measured by overall distribution of the modified Rankin Scale scores from 0 (no symptoms) to 6 (death). The primary safety outcome was the incidence of symptomatic intracranial hemorrhage within 48 hours.
RESULTS: Among 948 patients randomized (mean age, 67 years; 391 [41.2%] women), 948 (100%) completed the trial. The median (IQR) 90-day modified Rankin Scale score in the tirofiban group vs placebo group was 3 (1-4) vs 3 (1-4). The adjusted common odds ratio for a lower level of disability with tirofiban vs placebo was 1.08 (95% CI, 0.86-1.36). Incidence of symptomatic intracranial hemorrhage was 9.7% in the tirofiban group vs 6.4% in the placebo group (difference, 3.3% [95% CI, -0.2% to 6.8%]).
CONCLUSIONS AND RELEVANCE: Among patients with large vessel occlusion acute ischemic stroke undergoing endovascular thrombectomy, treatment with intravenous tirofiban, compared with placebo, before endovascular therapy resulted in no significant difference in disability severity at 90 days. The findings do not support use of intravenous tirofiban before endovascular thrombectomy for acute ischemic stroke.
TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR-IOR-17014167.
参考来源
- Qiu Z, Li F, Sang H, et al. Effect of Intravenous Tirofiban vs Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The RESCUE BT Randomized Clinical Trial. JAMA. 2022. PMID: 35943471. doi:10.1001/jama.2022.12584
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。